A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, US regulators announced on Wednesday. The US Food and Drug Administration approved Eli Lilly's Zepbound, or tirzepatide. The drug helped dieters lose about a quarter of their body weight, or 60 pounds (27 kilograms), in a recent study. Zepbound is the latest diabetes drug approved for weight loss, joining Novo Nordisk's Wegovy, a high-dose version of its diabetes treatment Ozempic. The FDA approved Lilly's drug for people who are considered obese, with a body mass index of 30 or higher, or those who are overweight with a related health condition, like high blood pressure, high cholesterol or diabetes. The drug should be paired with a healthy diet and regular exercise, the FDA said. In the US, at least 100 million adults and about 15 million children are considered obese. The drug tirzepatide in Zepbound and Mounjaro and semaglutide in Wegovy and Ozempic work by mimicking hormones that kick
There could be a more than $100 billion global market for such medicines, with sales climbing quickly through the end of the decade
Researchers showed that when energy-restricted diets were supplemented with Californian almonds or carbohydrate-rich snacks, both diets successfully lowered body weight by roughly 7kg
The pharma company published the results of phase two of the clinical trial of Retatrutide, showing impressive weight loss and regulation of blood sugar levels in undertrials
Novo and Lilly's experimental obesity pills helped people lose about 15% of body weight, similar to weight-loss shots on the market already, according to findings presented
Artificial sweeteners were also linked with higher risk of developing type 2 diabetes and cardiovascular disease, as well as of dying, according to the WHO
The drug maker claimed that the new drug Tirzepatide has enabled people with obesity or who are overweight to lose about 22.5 per cent of their body weight
North Korean leader's weight has long been tracked by spy agencies for clues about the stability of his regime.
After 4 weeks, teens on sleep plans increased their average sleep time by about 1.2 hours a night and lost an average of 2.1 kilograms
Researchers examined hospital records from 2002 to 2014 for more than 1.6 million women
People with mental health disorders are more likely to be obese than other individuals
People who were sedentary for 10 hours a day were 48 per cent more likely to die during the study than people who moved more
My weight gain is a result of the cook's calorific regime, says the author
Why exercise underwhelms for weight reduction remains an open question
There are so many versions, it's hard to know which one is best. Here's what the research says
The study of the appetite-dulling mutation was led by Dr. Sadaf Farooqi, professor of metabolism and medicine at the University of Cambridge, and Nick Wareham, an epidemiologist at the university
Researchers enrolled 183 individuals who were overweight or obese into a year-long programme
Obese children are at increased risk of diabetes, high blood pressure, asthma and sleep problems
Avocado consumers were 33% less likely to be overweight or obese
Researchers say, replacing whole grains for refined grains in diet increases calorie loss and speed up metabolism